ECM
INO icon

EMC Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

EMC Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,247
Closed -$250K – 130
2021
Q1 		$250K Buy
2,247
+986
+78% +$130K 0.18% 87
2020
Q4 		$134K Buy
+1,261
New +$168K 0.1% 91

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EMC Capital Management's INO Position: Q2 2021 in Review

EMC Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2021, closing a stake of 2,247 shares — an estimated $250K sold.

EMC Capital Management first reported a position in INO in Q4 2020 and held it in 2 quarters. The position peaked at $250K in Q1 2021. 211 funds tracked by Wall St. Rank hold INO as of Q2 2021.

  • EMC Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • EMC Capital Management sold 2,247 Inovio Pharmaceuticals shares in Q2 2021, an estimated $250K.
  • EMC Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • EMC Capital Management's Inovio Pharmaceuticals position peaked at $250K in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2021.

Based on EMC Capital Management's 13F filing for Q2 2021, filed 9 Aug 2021.